Quick Answer
Foghorn Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $80.88 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed an increase of +45.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $21.50 million | Q1 2020: $3.44 million | Q2 2020: $36.56 million | Q3 2020: $74.62 million | Q1 2021: $66.45 million | Q2 2021: $125.17 million | Q3 2021: $57.84 million | Q1 2022: $213.65 million | Q2 2022: $61.21 million | Q3 2022: $87.60 million | Q1 2023: $50.64 million | Q2 2023: $57.70 million | Q3 2023: $70.31 million | Q1 2024: $79.25 million | Q2 2024: $138.95 million | Q3 2024: $57.68 million | Q1 2025: $61.03 million | Q2 2025: $72.57 million | Q3 2025: $89.33 million.
- Over the full 7 years of available data (2019 to 2025), Foghorn Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 439.9%.
- Historical annual values: Fiscal year 2025: $80.88 million | Fiscal year 2024: $55.45 million | Fiscal year 2023: $80.34 million | Fiscal year 2022: $52.21 million | Fiscal year 2021: $101.14 million | Fiscal year 2020: $92.80 million | Fiscal year 2019: $14.98 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: